RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, has expanded its advisory relationships through the development of its Scientific Advisory Board (SAB) focused on PolyMedix’s basic scientific research. The SAB is comprised of world-renown scientists who will actively collaborate with PolyMedix to advance its preclinical portfolio of therapeutic drug candidates and PolyCide™ for biomaterials applications.
